• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15914 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2018 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Emicizumab for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with Haemophilia A (congenital Factor VIII deficiency) with or without Factor VIII inhibitors
2018 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Human tissue (surgical) wound treatments - laminectomy and tendon repair (AmnioFix, AmnioWrap and AmnioFix Injectable)
2018 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Purified human alpha1-proteinase inhibitor (A1-P1) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease
2018 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Endoscopic placement and removal of an intra-gastric balloon (IGB) for the management of overweight and obesity, in a high-risk patient
2018 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation for chronic major depressive episodes
2018 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) New item numbers and rebates for mobile radiology services
2018 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Purified human alpha1-proteinase inhibitor (A1-P1) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD)
2018 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Meniscal allograft transplantation for post-meniscectomy syndrome
2018 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Stem cell treatments within surgical specialities: what is the evidence?
2018 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Leaving surgical training: some of the reasons are in surgery
2018 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Day case hernia repair: weak evidence or practice gap?
2018 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Prostate artery embolisation: poor design and reporting impact the value of current systematic reviews
2018 Agency for Healthcare Research and Quality (AHRQ) Attention deficit hyperactivity disorder: diagnosis and treatment in children and adolescents
2018 Agency for Healthcare Research and Quality (AHRQ) Breastfeeding programs and policies, breastfeeding uptake, and maternal health outcomes in developed countries
2018 Agency for Healthcare Research and Quality (AHRQ) Drug therapy for early rheumatoid arthritis: a systematic review update
2018 Agency for Healthcare Research and Quality (AHRQ) Effectiveness of indoor allergen reduction in management of asthma
2018 Agency for Healthcare Research and Quality (AHRQ) Intermittent inhaled corticosteroids and long-acting muscarinic antagonists for asthma
2018 Agency for Healthcare Research and Quality (AHRQ) Lower limb prostheses: measurement instruments, comparison of component effects by subgroups, and long-term outcomes
2018 Agency for Healthcare Research and Quality (AHRQ) Mobile applications for self-management of diabetes
2018 Agency for Healthcare Research and Quality (AHRQ) Noninvasive nonpharmacological treatment for chronic pain: a systematic review
2018 Agency for Healthcare Research and Quality (AHRQ) Nonsurgical treatments for urinary incontinence in women: a systematic review update
2018 Agency for Healthcare Research and Quality (AHRQ) Patient navigation models for lung cancer
2018 Agency for Healthcare Research and Quality (AHRQ) Physiologic predictors of severe injury: systematic review
2018 Agency for Healthcare Research and Quality (AHRQ) Psychological and pharmacological treatments for adults with posttraumatic stress disorder: a systematic review update
2018 Agency for Healthcare Research and Quality (AHRQ) Role of immunotherapy in the treatment of asthma
2018 Agency for Healthcare Research and Quality (AHRQ) Sodium and potassium intake: effects on chronic disease outcomes and risks
2018 Agency for Healthcare Research and Quality (AHRQ) Stroke prevention in patients with atrial fibrillation: a systematic review update
2018 Agency for Healthcare Research and Quality (AHRQ) Treatment for bipolar disorder in adults: a systematic review
2018 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of ambulatory electrocardiography technologies for the diagnosis of cardiac arrhythmia]
2018 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of the ultrasonic flowmeter for verification of graft patency during coronary artery bypass grafting]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Femoral neck fracture: evaluation of the hospital care process]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy and safety of bariatric surgery in individuals with morbid obesity]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy, safety, and usefulness of genistein in patients with Sanfilippo syndrome]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Analysis of diagnostic performance of transbronchial lung biopsy using cryoprobe (cryobiopsy) in the study of diffuse lung diseases]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Enzyme replacement therapy in lysosomal storage diseases: systematic review and budgetary impact. Update]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Proton therapy in cancer treatment. Update]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Shoulder arthroscopy: appropriate use]
2018 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Effectiveness and cost-effectiveness of bilateral cochlear implants in children and adults]
2018 The Regional Health Technology Assessment Centre (HTA-centrum) Effects of lung volume reduction with endobronchial valves in patients with severe chronic obstructive pulmonary disease. Updated report
2018 The Regional Health Technology Assessment Centre (HTA-centrum) Gender affirmation surgery for gender dysphoria - effects and risks
2018 The Regional Health Technology Assessment Centre (HTA-centrum) Effects of passive movement therapy in patients with stroke, spinal cord injury, or need of intensive care
2018 The Regional Health Technology Assessment Centre (HTA-centrum) Efficacy of the Swedish model for physical activity on prescription
2018 The Regional Health Technology Assessment Centre (HTA-centrum) Triage for prioritisation in the emergency department
2018 National Institute for Health and Care Excellence (NICE) Golimumab for treating non-radiographic axial spondyloarthritis. NICE technology appraisal guidance 497
2018 National Institute for Health and Care Excellence (NICE) Lenvatinib with everolimus for previously treated advanced renal cell carcinoma. NICE technology appraisal guidance 498
2018 National Institute for Health and Care Excellence (NICE) Glecaprevir–pibrentasvir for treating chronic hepatitis C. NICE technology appraisal guidance 499
2018 National Institute for Health and Care Excellence (NICE) Ceritinib for untreated ALK-positive non-small-cell lung cancer. NICE technology appraisal guidance 500
2018 National Institute for Health and Care Excellence (NICE) Intrabeam radiotherapy system for adjuvant treatment of early breast cancer. NICE technology appraisal guidance 501
2018 National Institute for Health and Care Excellence (NICE) Ibrutinib for treating relapsed or refractory mantle cell lymphoma. NICE technology appraisal guidance 502
2018 National Institute for Health and Care Excellence (NICE) Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer. NICE technology appraisal guidance 503
2018 National Institute for Health and Care Excellence (NICE) Pirfenidone for treating idiopathic pulmonary fibrosis. NICE technology appraisal guidance 504
2018 National Institute for Health and Care Excellence (NICE) Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C. NICE technology appraisal guidance 507
2018 National Institute for Health and Care Excellence (NICE) Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee. NICE technology appraisal guidance 508
2018 National Institute for Health and Care Excellence (NICE) Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer. NICE technology appraisal guidance 509
2018 National Institute for Health and Care Excellence (NICE) Brodalumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 511
2018 National Institute for Health and Care Excellence (NICE) Tivozanib for treating advanced renal cell carcinoma. NICE technology appraisal guidance 512
2018 National Institute for Health and Care Excellence (NICE) Obinutuzumab for untreated advanced follicular lymphoma. NICE technology appraisal guidance 513
2018 National Institute for Health and Care Excellence (NICE) Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen. NICE technology appraisal guidance 515
2018 National Institute for Health and Care Excellence (NICE) Cabozantinib for treating medullary thyroid cancer. NICE technology appraisal guidance 516
2018 National Institute for Health and Care Excellence (NICE) Avelumab for treating metastatic Merkel cell carcinoma. NICE technology appraisal guidance 517
2018 National Institute for Health and Care Excellence (NICE) Tocilizumab for treating giant cell arteritis. NICE technology appraisal guidance 518
2018 National Institute for Health and Care Excellence (NICE) Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 520
2018 National Institute for Health and Care Excellence (NICE) Guselkumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 521
2018 National Institute for Health and Care Excellence (NICE) Midostaurin for untreated acute myeloid leukaemia. NICE technology appraisal guidance 523
2018 National Institute for Health and Care Excellence (NICE) Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma. NICE technology appraisal guidance 524
2018 National Institute for Health and Care Excellence (NICE) Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. NICE technology appraisal guidance 525
2018 National Institute for Health and Care Excellence (NICE) Arsenic trioxide for treating acute promyelocytic leukaemia. NICE technology appraisal guidance 526
2018 National Institute for Health and Care Excellence (NICE) Beta interferons and glatiramer acetate for treating multiple sclerosis. NICE technology appraisal guidance 527
2018 National Institute for Health and Care Excellence (NICE) Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 529
2018 National Institute for Health and Care Excellence (NICE) Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy. NICE technology appraisal guidance 530
2018 National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. NICE technology appraisal guidance 531
2018 National Institute for Health and Care Excellence (NICE) Ocrelizumab for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 533
2018 National Institute for Health and Care Excellence (NICE) Dupilumab for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 534
2018 National Institute for Health and Care Excellence (NICE) Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine. NICE technology appraisal guidance 535
2018 National Institute for Health and Care Excellence (NICE) Alectinib for untreated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 536
2018 National Institute for Health and Care Excellence (NICE) Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 537
2018 National Institute for Health and Care Excellence (NICE) Dinutuximab beta for treating neuroblastoma. NICE technology appraisal guidance 538
2018 National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma. NICE technology appraisal guidance 540
2018 National Institute for Health and Care Excellence (NICE) Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. NICE technology appraisal guidance 541
2018 National Institute for Health and Care Excellence (NICE) Cabozantinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 542
2018 National Institute for Health and Care Excellence (NICE) Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 543
2018 National Institute for Health and Care Excellence (NICE) Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma. NICE technology appraisal guidance 544
2018 National Institute for Health and Care Excellence (NICE) Gemtuzumab ozogamicin for untreated acute myeloid leukaemia. NICE technology appraisal guidance 545
2018 National Institute for Health and Care Excellence (NICE) Padeliporfin for untreated localised prostate cancer. NICE technology appraisal guidance 546
2018 National Institute for Health and Care Excellence (NICE) Tofacitinib for moderately to severely active ulcerative colitis. NICE technology appraisal guidance 547
2018 National Institute for Health and Care Excellence (NICE) Decitabine for untreated acute myeloid leukaemia (terminated appraisal). NICE technology appraisal guidance 548
2018 National Institute for Health and Care Excellence (NICE) Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal). NICE technology appraisal guidance 549
2018 National Institute for Health and Care Excellence (NICE) Vandetanib for treating medullary thyroid cancer. NICE technology appraisal guidance 550
2018 National Institute for Health and Care Excellence (NICE) Lenvatinib for untreated advanced hepatocellular carcinoma. NICE technology appraisal guidance 551
2018 National Institute for Health and Care Excellence (NICE) Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia. NICE technology appraisal guidance 552
2018 National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. NICE technology appraisal guidance 554
2018 National Institute for Health and Care Excellence (NICE) Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults. NICE interventional procedures guidance 634
2018 National Institute for Health and Care Excellence (NICE) Bronchial thermoplasty for severe asthma. NICE interventional procedures guidance 635
2018 National Institute for Health and Care Excellence (NICE) Transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain. NICE interventional procedures guidance 632
2018 National Institute for Health and Care Excellence (NICE) Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions. NICE interventional procedures guidance 633
2018 National Institute for Health and Care Excellence (NICE) Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis. NICE interventional procedures guidance 631
2018 National Institute for Health and Care Excellence (NICE) Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma. NICE interventional procedures guidance 630
2018 National Institute for Health and Care Excellence (NICE) Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer. NICE interventional procedures guidance 628
2018 National Institute for Health and Care Excellence (NICE) Leadless cardiac pacemaker implantation for bradyarrhythmias. NICE interventional procedures guidance 626
2018 National Institute for Health and Care Excellence (NICE) Superior rectal artery embolisation for haemorrhoids. NICE interventional procedures guidance 627